Fragments to link. A multiple docking strategy for second site binders

Fragment based drug discovery employs growing and linking strategies for optimization. Here we report the binding mode prediction of multiple fragments bound to a single target using a sequential docking methodology employing Glide to support the identification and linking of fragment hits. Sampling and scoring accuracy for the first and second site binders in self- and cross-docking situations is assessed.

[1]  Gang Liu,et al.  Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.

[2]  Gang Liu,et al.  Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[3]  Chris Abell,et al.  Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. , 2009, Angewandte Chemie.

[4]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[5]  Hongming Wang,et al.  Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide , 2009, J. Comput. Aided Mol. Des..

[6]  Chris Abell,et al.  Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. , 2010, Journal of the American Chemical Society.

[7]  Richard J. Hall,et al.  Docking performance of fragments and druglike compounds. , 2011, Journal of medicinal chemistry.

[8]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[9]  Robert Kiss,et al.  Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes , 2010, J. Chem. Inf. Model..

[10]  G. F. Ruda,et al.  Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase , 2010, Bioorganic & medicinal chemistry.

[11]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[12]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[13]  Alan E Mark,et al.  Missing fragments: detecting cooperative binding in fragment-based drug design. , 2012, ACS medicinal chemistry letters.

[14]  György M. Keserü,et al.  Multiple ligand docking by Glide: implications for virtual second-site screening , 2012, Journal of Computer-Aided Molecular Design.

[15]  Mark Whittaker,et al.  Compound Design by Fragment‐Linking , 2011, Molecular informatics.

[16]  Edward R Zartler,et al.  Practical aspects of NMR-based fragment discovery. , 2007, Current topics in medicinal chemistry.

[17]  Ramaswamy Nilakantan,et al.  CONFIRM: connecting fragments found in receptor molecules , 2008, J. Comput. Aided Mol. Des..

[18]  T. Blundell,et al.  Structural biology in fragment-based drug design. , 2010, Current opinion in structural biology.

[19]  György G. Ferenczy,et al.  Thermodynamics of Fragment Binding , 2012, J. Chem. Inf. Model..

[20]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[21]  Gang Liu,et al.  Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. , 2003, Journal of medicinal chemistry.

[22]  Gang Liu,et al.  Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. , 2003, Journal of medicinal chemistry.